Similar articles

• Targets in apoptosis signaling: promise of selective anticancer therapy.

  Nimmanapalli R, Bhalla K. Nimmanapalli R, et al. Methods Mol Biol. 2003;223:465-83. doi: 10.1385/1-59259-329-1:465. Methods Mol Biol. 2003. PMID: 12777745 Review. No abstract available.
• Defining characteristics of Types I and II apoptotic cells in response to TRAIL.

  Ozören N, El-Deiry WS. Ozören N, et al. Neoplasia. 2002 Nov-Dec;4(6):551-7. doi: 10.1038/sj.neo.7900270. Neoplasia. 2002. PMID: 12407450 Free PMC article.
• Effects of antioxidants and caspase-3 inhibitor on the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human PLC/PRF/5 cells.

  Wu SJ, Ng LT, Lin CC. Wu SJ, et al. Eur J Pharmacol. 2005 Aug 22;518(2-3):96-106. doi: 10.1016/j.ejphar.2005.06.021. Eur J Pharmacol. 2005. PMID: 16054126
• Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.

  Aggarwal BB, Bhardwaj U, Takada Y. Aggarwal BB, et al. Vitam Horm. 2004;67:453-83. doi: 10.1016/S0083-6729(04)67023-3. Vitam Horm. 2004. PMID: 15110190 Review.
• Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.

  Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. Herr I, et al. Cancer Res. 2003 Jun 15;63(12):3112-20. Cancer Res. 2003. PMID: 12810637